Anemia Management News

WASHINGTON — Compared to epoetin alfa, roxadustat was more effective in raising hemoglobin levels and used less iron therapy in incident patients with kidney disease on dialysis, according to results from U.S. and European studies presented here.

WASHINGTON — Results from the phase 3 OLYMPUS trial presented here show the investigational hypoxia-inducible factor prolyl hydroxylase inhibitor drug roxadustat significantly increased hemoglobin levels in patients with anemia and chronic kidney disease compared to those treated with placebo.

WASHINGTON — Data presented here from the ROCKIES phase 3 trial showed use of the investigational hypoxia-inducible factor prolyl hydroxylase inhibitor drug roxadustat led to greater increases in hemoglobin levels compared to use of epoetin alfa in patients with ESKD and anemia.

WASHINGTON — Roxadustat showed efficacy with no increased cardiovascular risk for patients with anemia from chronic kidney disease, according to pooled efficacy data presented here at ASN Kidney Week.

WASHINGTON — Lower hemoglobin levels may be a strong and independent predictor of higher risk of major adverse kidney events within 7 days after cardiac surgery or admittance to the ICU, according to data presented at ASN Kidney Week.

Preservation of residual kidney function reduces morbidity, improves survival and offers other benefits to patients with ESKD. However, more study is needed to understand the mechanisms of residual kidney function along with methods and treatments that can successfully extend preservation, according to a recently published study.

Researchers from Denmark found the presence of anemia was associated with an increased risk for incident dialysis in patients with chronic kidney disease. In addition, for these patients and those already on dialysis, anemia increased risks for hospitalization, mortality and major adverse cardiovascular events.

Ferric citrate complex can help increase hemoglobin and reduce serum phosphate in patients with advanced chronic kidney disease, a recently published study shows.

Two phase 3 trials in a Chinese patient population with kidney disease and anemia showed use of the oral hypoxia-inducible factor prolyl hydroxlase inhibitor roxadustat was superior to placebo in increasing hemoglobin levels in patients not on dialysis and was noninferior to erythropoietin in patients undergoing dialysis.

A study of almost 195,000 patients on hemodialysis in Japan showed a higher risk of mortality among those treated with longer-acting anemia drugs compared to those treated with shorter-acting drugs.